Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988650 | 1.00 | PDE4B (0.52) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL1422394 | 1.00 | PDE4B (0.52) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL12609696 | 0.93 | PDE4B (0.58) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL503247 | 0.93 | PDE4B (0.58) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL29537645 | 0.93 | PDE4B (0.58) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL20548030 | 0.92 | PDE4B (0.46) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL20548031 | 0.92 | PDE4B (0.46) | PDE4BNR1H2HPGDSALDH1A1MAPT | |
| SCHEMBL25203147 | 0.91 | NAMPT (0.56) | PDE4BNR1H2ALDH1A1MAPTNAMPT | |
| SCHEMBL21708067 | 0.91 | NAMPT (0.50) | PDE4BNR1H2ALDH1A1MAPTMEN1 | |
| SCHEMBL19074633 | 0.91 | NAMPT (0.50) | PDE4BNR1H2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024142096-A1 | PROCESS FOR PREPARATION OF NIRAPARIB TOSYLATE AND ITS INTERMEDIATES | DR. REDDY’S LABORATORIES LIMITED (IN) | 2024-07-04 | — | — | WO | disclosed |
| CN-118271233-A | Nilaparil manufacturing method | 特沙诺有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117964546-B | Preparation method of nilaparib intermediate | 成都硕德药业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118084772-A | Nilapatinib intermediate, preparation method and method for preparing Nilapatinib by using same | 重庆博腾制药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117964546-A | Preparation method of nilaparib intermediate | 成都硕德药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-11629137-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-110753684-A | Method for producing nilapali | 特沙诺有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2019072237-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019036441-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS USA, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885 |
| US-11629137-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | PDE4B 1355/4885NR1H2 4776/4885HPGDS 695/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.